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Summary We have used a metastasis-related human cDNA isolated from a liver metastasis from a colonic
adenocarcinoma to screen a human breast carcinoma cDNA library for homologous sequences. Nucleotide
sequence analysis of positive clones revealed that the cDNA represents a ribosomal phosphoprotein, P2. The
expression of P2 mRNA was significantly higher (Student's t test, one tail; P.0.01) in seven fibroadenomas
than in seven carcinomas, with an average five-fold difference. This enhanced expression level of P2 mRNA in
benign fibroadenomas compared with malignant carcinomas is contrary to that expected, based on earlier
work with normal colonic mucosa, colorectal carcinoma and hepatic metastasis. The identification of gene
transcripts which differ in abundance and correlate with the metastatic phenotype may be of considerable
importance both as diagnostic aids and in defining the changes associated with tumour progression and
metastasis at the molecular level. The possible role that ribosomal proteins may play in the progression of
carcinoma of the breast is discussed.
Breast carcinomas exhibit great diversity in their biological
behaviour. This is illustrated in the fact that some patients
can present with distant metastases within one or two years
whereas for others up to 10-25 years can pass before the
development of recurrent disease. This difference in
behaviour is reflected in the survival time of women with
breast cancer, which can range from a few months to 25
years before death from the disease (Blamey et al., 1979;
Brinkley & Haybittle, 1975). The absence/presence of local or
distant metastases at the time of presentation is a very good
prognostic indicator (Fisher et al., 1984). Greater precision in
the detection of metastases at an early stage or development
of assays which could identify those tumours with greater
metastatic potential would be of value in the design of
therapeutic regimes.
There are multiple factors involved in the complex
phenomenon of tumour progression, invasion and metastasis
(Nowell, 1976, 1986; Fidler & Hart, 1982; Liotta, 1986).
There is evidence that malignant tumours contain multiple
subpopulations of cells with differing metastatic abilities
(Fidler & Hart, 1982) and the existence of tumour cell
heterogeneity within breast cancers is well documented (Hep-
pner et al., 1984). The fundamental mechanisms of invasion
and metastasis are being studied but the complexity of the
process has forced investigators to focus on one step at a
time (Liotta, 1986). There is an obvious need to extend such
studies to the molecular genetic level.
One approach which enables the investigation of the
specific nature of cellular changes associated with metastasis
is the differential screening of cDNA libraries. This has been
used to identify genes which have altered expression patterns
in different disease or developmental states, such as human
leukaemia leukocyte-specific mRNAs (Shiosaka & Saunders,
1982) and the fibronectin mRNA levels in metastasising rat
prostatic cancer cells (Schalken et al., 1988). The procedure
has also been used successfully by Steeg et al. (1988) and
Dear et al. (1988) to identify mRNAs whose expression
correlates with the non-metastatic phenotype. Differential
screening was also used by Elvin et al. (1988) to isolate a
cDNA clone, termed pLM59, which is more highly expressed
in liver metastases of colorectal carcinomas than in primary
colorectal tumours and normal tissue.
It was of interest to us to evaluate the relative levels of
expression of pLM59 in benign and malignant breast
tumours and metastatic tissue which may indicate that this
cDNA is associated with other malignancies in addition to
colorectal carcinoma. We have compared pLM59-
homologous mRNA levels in fibroadenomas of the breast
relative to carcinomas of the same tissue. This paper also
describes the isolation of a full-length cDNA clone
homologous to the human cDNA pLM59 and the determina-
tion of the nucleotide sequence. Southern analysis has
revealed EcoRI and HindlIl restriction fragment length
polymorphisms (RFLPs) within the sequences homologous to
the pLM59 probe.
Materials and methods
Tissues
The breast carcinoma used to construct the cDNA library
was surgically removed from a post-menopausal patient, and
samples were placed immediately into liquid nitrogen. Upon
histological analysis, the sample was found to be a poorly
differentiated infiltrating duct carcinoma with no evidence of
lymph node metastases (T2NoMo: see Hermanek & Sobin,
1987). Other tissues used in this study include other breast
carcinomas and associated lymph nodes draining the affected
breast, benign fibroadenomas and normal tissue (placenta or
lymphocyte/lymphoblastoid cells). We used normal tissue
from 47 individuals and tumour tissue from 49 patients.
Material,s
G-tailed plasmid vector pUC9 was purchased from Phar-
macia. Radioisotopes were from Amersham International
plc. Avian myeloblastosis virus reverse transcriptase was
from Life Sciences Inc. (St Petersberg, USA); all other
enzymes were from Bethesda Research Laboratories or
Sigma Chemical Co. Nylon membranes were purchased from
Amersham International plc.
DNA and RNA preparation
DNA and RNA samples were prepared as described
previously (Varley et al., 1987; Whittaker et al., 1986). All
solutions containing RNA and DNA were stored at - 70°C.
Preparation ofthe cDNA library
Purification of poly(A)+ RNA was according to the method
of Maniatis et al. (1982). Complementary DNA was made by
the method of Gubler and Hoffman (1983). The first strand
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was synthesised using reverse transcriptase, followed by
second strand synthesis using RNase H and DNA
polymerase I. The cDNA was incorporated into the vector
pUC9 by homopolymer tailing, and then transformed into
Escherichia coli, JM83.
Screening
Colony hybridisation was by the method of Grunstein and
Hogness (1975) using nylon hybridisation membranes. The
pLM59 cDNA probe was radiolabelled by random hexamer
priming of restriction fragments (Feinberg & Vogelstein,
1983). DNA from colonies which hybridised to the probe was
prepared by the method of Birnboim and Doly (1979).
DNA sequence analysis
Sequencing reactions were based on the dideoxy method
described by Sanger et al. (1977), using a single-stranded
template DNA from the M13 series of bacteriophage vectors.
An alternative strategy employed was the Sequenase DNA
sequencing kit from United States Biochemical Corporation
(Cleveland, USA).
Southern blot analysis
All DNA analysis was performed as described previously
(Varley et al., 1987; Whittaker et al., 1986). The stringency of
washing conditions for all filters was 0.5 x SSC at 65'C,
unless otherwise stated.
Northern blot analysis
Total RNA was incubated at 55°C for 15 min in a buffer
containing 1.1 M glyoxal and 75% deionised formamide, and
separated by electrophoresis immediately on a 1% agarose
gel in 1 x MOPS buffer (0.02 M MOPS; 5 mM sodium
acetate; 0.1 mM EDTA; pH 7) (Maniatis et al., 1982). After
electrophoresis, the RNA was transferred onto nylon filters
and cross-linked by UV irradiation. Finally the glyoxalation
was reversed by baking the filters at 80°C for 1 h. Filters
were pre-hybridised for 2 h at 45'C in 6 x SSC, 50%
deionised formamide, 5 x Denhardts, 0.1% SDS and
250fig ml-' denatured salmon testis DNA. Hybridisation
was for a minimum of 14 h at 45°C in 6 x SSC, 50%
deionised formamide, I x Denhardts, 0.1% SDS, 250 ytg ml-'
denatured salmon testis DNA and 10% dextran sulphate.
Filters were washed to a stringency of 2 x SSC, 0.1% SDS at
65'C for the pLM59 probe, or 0.2 x SSC, 0.1% SDS at 65'C
for the 7S RNA probe, dried and autoradiographed using
either Kodak X-Omat or Fuji RX film with intensifying
screens at -70'C.
Results
Screening the cDNA library
A cDNA library of over 21,000 different clones representing
poly(A) + RNA from a single human breast carcinoma
sample was constructed. Initially, a portion (325 colonies or
0.14%) of this library was screened by hybridisation to the
metastasis-related cDNA sequence pLM59 (Elvin et al., 1988)
Two clones were identified as having homology with pLM59
sequences. These sequences, designated C328-15 and C328-
16, were selected for further analysis.
Characterisation ofselected cDNAs: sequence data
Restriction mapping and nucleotide sequence analysis
revealed that clones C328-15 and C328-16 are separate, com-
pletely overlapping cDNAs representing the same mRNA
species (data not shown).
Computer-aided comparison of the cDNA sequences with
those in the EMBL DNA sequence database revealed no
homology with any known gene. Using the cDNA sequence
from C328-15, the amino acid sequence of the putative trans-
lation product was deduced and this was used to search the
NBRF protein sequence database for homologous protein
sequences. A region of strong homology was found between
the amino acid sequence of the putative C328-15-derived
protein and the amino acid sequence of acidic ribosomal
phosphoproteins from rat (Lin et al., 1982) and brine shrimp
(Amons et al., 1979, 1982; Maassen et al., 1985). Comparison
with more recently published cDNA sequences indicated that
clones C328-15 and C328-16 are very similar to nucleotide
sequences which encode the human ribosomal phospho-
protein P2 (Rich & Steitz, 1987). Thus, the pLM59 cDNA
used as the probe initially corresponds to the mRNA for the
human P2 protein.
Comparison ofthe P2 and C328-15 cDNA sequences
Alignment of the cDNA sequences encoding the P2 protein
reported by Rich and Steitz (1987) and the clone C328-15
shows 100% identity in the putative coding and the 3' non-
translated regions, and 83% homology over the 5' non-
coding region (Figure 1). Clone C328-15 has the same few 5'
and 3' nucleotides as the P2 cDNA already demonstrated to
be full-length by Rich and Steitz (1987), and therefore C328-
15 probably represents a complete cDNA for the P2 mRNA.
There are three non-homologous regions in the 5' non-
translated sequence. The first is the absence in the C328-15
sequence of an adenosine residue at position 12 of the P2
sequence. This discrepancy is interesting in that in the C328-
15 cDNA there is no longer a putative ATG initiation codon
at this position. This ATG, if present, may be the start of a
short open reading frame encoding an octapeptide, upstream
of the P2 coding sequence as suggested by Rich and Steitz
(1987), although no evidence was presented by these authors
to support the existence of this octapeptide.
Another difference between the published P2 sequence and
that of the C328-15 cDNA is the absence of a 9 bp segment
of DNA in C328-15 corresponding to nucleotides 44-52 of
the P2 cDNA. This region of DNA is identical to the 9 bp
immediately 3' of the discrepancy, and could represent a
cloning artefact, with 9 bp having been lost or gained from
one of the cDNAs.
The third difference is the orientation of a GC pair at
positions 28 and 29 of the P2 cDNA.
Analysis ofgenomic sequences
We screened genomic DNA from 33 breast carcinoma
DNAs, lymph node metastasis DNAs from 10 of these
tumours and 25 normal samples (placental or lymphocyte
DNAs) for pLM59-homologous sequences. The probe detects
four bands in EcoRI digests of >20 kbp, 9.2 kbp, 6.4kbp
and 2.5 kbp, as shown in Figure 2. We did not detect any
amplification or alteration to pLM59 sequences in any of the
breast tumour or metastasis samples. In addition, an 8.8 kbp
band was detected in 11 out of 33 (33%) of the carcinoma
DNAs and also (where available) in the lymph node metas-
tasis DNA from each of these tumours. This band was also
seen in 10 out of 25 normal samples (40%). Since another
digest (BamHI) of the DNA samples showed no pattern
differences, it appears that the 8.8 kbp EcoRI fragment
represents a restriction site polymorphism, rather than a
tumour-specific somatic rearrangement. To confirm this, laser
scanning densitometry was performed on the autoradio-
graphs (data not shown). This indicated that the appearance
of the 8.8 kbp allele occurred concomitantly with an equiva-
lent decrease in the intensity of the 2.5 kbp band, thus sug-
gesting that the 8.8 kbp and the 2.5 kbp bands are allelic.
Demonstration of the Mendelian inheritance of the 8.8 kbp
allele using the extended families of the CEPH collection
showed that the 8.8 kbp allele is inherited in the expected
manner (data not shown). These data also show that the
8.8 kbp allele is not X chromosome-linked, because the allele
can clearly be passed from father to son.DIFFERENTIAL EXPRESSION OF P2 85
P2 A GC CTCCGCCGC
8-15 CTTTTCCTCCC.TGTCGCCACCGAGGTCGCACGCGTGAGACTT ......... CTCCGCCG
-14 CAGACGCCGCCGCGATGCGCTACGTCGCCTCCTACCTGCTGGCTGCCCTAGGGGGCAACT
M R Y V A S Y L L A A L G G N S
47 CCTCCCCCAGCGCCAAGGACATCAAGAAGATCTTGGACAGCGTGGGTATCGAGGCGGACG
S P S A K D I K K I L D S V G I E A D D
107 ACGACCGGCTCAACAAGGTTATCAGTGAGCTGAATGGAAAAAACATTGAAGACGTCATTG
D R L N K V I S E L N G K N I E D V I A
167 CCCAGGGTATTGGCAAGCTTGCCAGTGTACCTGCTGGTGGGGCTGTAGCCGTCTCTGCTG
Q G I G K L A S V P A G G A V A V S A A
227 CCCCAGGCTCTGCAGCCCCTGCTGCTGGTTCTGCCCCTGCTGCAGCAGAGGAGAAGAAAG
P G S A A P A A G S A P A A A E E K K D
287 ATGAGAAGAAGGAGGAGTCTGAAGAGTCAGATGATGACATGGGATTTGGCCTTTTTGATT
E KIK E E S E E S D ID D M G F G L F D I
-15
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286
346
347 AAATTCCTGCTCCCCTGCAAATAAAGCCTTTTTACACATCAAAAAAAAAA 396
Figure 1 Nucleotide sequence of clone C328-15, the full-length cDNA identified with pLM59, and the putative amino acid
sequence of the gene product. This is also the sequence of the ribosomal phosphoprotein P2, with certain differences in the 5'
non-translated region indicated above the C328-15 sequence (Rich & Steitz, 1987). The probable polyadenylation signal is
underlined. The carboxy-terminal residues conserved in other ribosomal P proteins are boxed.
We attempted to simplify the pattern of hybridising bands
in the Southern analysis by probing with smaller fragments
of pLM59. Both a 98 bp 5' fragment and a 195 bp 3' frag-
ment hybridised to all the same bands (data not shown).
These results indicate several possibilities. There may be four
or five related sequences in the genome, either pseudogenes
or functional P2 genes, or alternatively there may be a mul-
tigene family with sufficient homology to cross-hybridise to
the pLM59-derived probe under the conditions used.
Southern filters were washed in 0.5 x SSC at 65°C; condi-
tions which allow 16% nucleotide mismatches between hyb-
ridising sequences.
Further analysis has indicated the presence of a HindlIl
restriction fragment length polymorphism (RFLP) yielding
allelic 8.0 kbp and 4.7 kbp fragments (Figure 2). Out of a
small sample of normal DNAs 63% (10/16) were homo-
zygous for the 4.7 kbp allele, 12% (2/16) were homozygous
for the 8.0 kbp allele and 25% (4/16) were heterozygous. The
existence of more than one allele for this gene raises the
question of an association of these alleles with breast cancer.
Neither the EcoRI nor the HindlIl RFLPs correlate with the
diseased state in the samples used in this study, and as such
are of limited interest in the diagnosis of aggressive tumours.
Expression ofthe P2 gene
The 349 bp pLM59 cDNA probe was used to estimate the
level of expression of the P2 gene(s) in a panel of seven
breast carcinoma total RNA samples and seven breast
fibroadenoma total RNA samples, by Northern blotting
(Figure 3). Electrophoresis of 10 jig of total RNA from these
tissue samples was followed by Northern blotting and hyb-
ridisation to the 32P-labelled pLM59 cDNA. The resulting
autoradiograph was subjected to scanning laser densitometry
to quantify the relative amounts of pLM59-homologous
mRNA in each track. As an internal control for the amount
of RNA transferred, the filter was stripped and rehybridised
to the mouse 7S small cytoplasmic RNA (Balmain et al.,
1982). The densitometry data generated with the pLM59
probe was adjusted according to the level of signal with the
7S probe. The results show that, on average, the level of
expression of the pLM59 mRNA in fibroadenomas is 5.4-
fold that of carcinomas (Figure 4). The higher level of exp-
ression of the pLM59 mRNA in fibroadenomas is significant
under the Student's t test (one tail; Ps<0.01).
There is a single mRNA species of approximately 630
nucleotides identified by the pLM59 cDNA (Figure 3), which
is in agreement with the estimated size of the P2 mRNA (600
nucleotides: Rich & Steitz, 1987). This indicates that of the
multiple loci seen in Southern blots, either only one locus is
transcriptionally active, or if more than one locus is active,
that only one size of transcription product is made. The
results shown in Figure 3 indicate that the P2 mRNA is
moderately abundant in breast tumours.
Discussion
We have used the metastasis-associated cDNA pLM59
isolated by Elvin et al. (1988) to identify two homologous
clones from a breast carcinoma cDNA library. Sequence
analysis of these clones has shown them to be almost iden-
tical to the sequence encoding the human ribosomal phos-
phoprotein P2 (Rich & Steitz, 1987). The pLM59 cDNA
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Figure 2 The genomic organisation of pLM59-homologous
sequences as shown by Southern analysis. This example shows (a)
breast carcinoma DNA samples and DNA from the correspon-
ding lymph node metastases (4pg) digested with EcoRI and
probed with pLM59 (see Materials and methods). The EcoRI
RFLP is seen as the appearance of a band of 8.8 kbp in certain
tumours. When this band is present in the primary tumour it is
also present in the lymph node metastasis. C, carcinoma; L,
lymph node metastasis. There is also a Hindlll RFLP (b) as seen
here in two examples of colonic carcinoma. The 8.0 kbp and the
4.7 kbp Hindlll fragments seen with the pLM59 probe are allelic.
Both RFLPs are present in the DNA from normal individuals,
and neither RFLP correlates with carcinoma of the breast or
colon. Sizes are in kilobase pairs.
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Figure 3 Expression of the P2 gene(s) in breast fibroadenomas
and carcinomas, as shown by Northern blotting. a, lOtLg of total
RNA was electrophoresed and blotted according to Materials
and methods, and the filters were probed with pLM59. After
washing in 2 x SSC at 65°C the filters were autoradiographed at
- 70°C for 60 h. The filters were then stripped and rehybridised
to the mouse 7S RNA (Balmain et al., 1982) as an internal
control for the amount of RNA on the filters (b). F,
fibroadenomas of the breast; C, breast carcinomas. The size of
the P2 transcript is shown in nucleotides.
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Figure 4 Relative levels of expression of P2 gene(s) in the breast
fibroadenoma and carcinoma samples shown in Figure 3. Laser
scanning densitometry data were adjusted according to the level
of signal with the 7S RNA probe, and expressed as a percentage
of the highest signal obtained. F, fibroadenoma (hatched bars);
C, carcinoma (solid bars).
probe detects a single mRNA species of 630 nucleotides, by
Northern analysis (Figure 3). In the tissue samples used in
this study (seven breast carcinomas, seven fibroadenomas of
the breast), the abundance of pLM59-homologous mRNA in
fibroadenomas was significantly higher than in carcinomas
(Student's t test, one tail; P<0.01), with an average of
5.4-fold higher levels (Figure 4). This is in contrast to the
results obtained by Elvin et al. (1988), who found that the
expression of pLM59 is enhanced in a liver metastasis com-
pared with a primary colon carcinoma and normal colonic
mucosae.
In addition to these expression data, the cDNA library
from which C328-15 and C328-16 were isolated had under-
gone two rounds of differential screening with probes derived
from one carcinoma and one fibroadenoma. In this
differential screening, the pLM59-homologous mRNA
appeared to be more highly abundant in the fibroadenoma-
derived probe than in the carcinoma-derived probe. These
results seem paradoxical as the pLM59 cDNA was expected
to be more highly expressed in the malignant tumour sam-
ples, as is the case with colonic tissue, than in the benign
breast tissue. It is difficult to make comparisons between
different tissue types concerning levels of gene expression.
The routes along which different tissues, and indeed individ-
ual tumours in the same tissue, progress towards malignancy
may vary significantly and be reflected in different profiles of
gene expression. There is a degree of overlap in the abun-
dance of pLM59-homologous mRNA in both the breast
carcinomas and the fibroadenomas in this study, and in the
primary colon carcinomas and secondary tumours examined
by Elvin et al. (1988). Larger sample sizes are required to
predict accurately whether pLM59 may or may not be imp-
licated in these and other human tumours.
Southern analysis using the P2 cDNA, pLM59, revealed a
complex genomic organisation suggestive of either multiple
copies of the P2 gene, the presence of pseudogenes or a
family of related genes (Figure 2). Which of these possibilities
is the case has yet to be resolved. There are also RFLPs in
EcoRI- and HindIll-digested DNA from a proportion of all
individuals, but the presence of the RFLP does not correlate
with the primary tumours of breast or colon, or the metas-
tases from these carcinomas.
The ribosomal phosphoprotein P2 is the functional
counterpart of the eL12 protein from Artemia salina (Amons
et al., 1979), the P2 protein of rat (Lin et al., 1982) and the
YPA1 (YL44c) protein of Saccharomyces cerevisiae
ribosomes (Itoh, 1981). The bacterial equivalent in
Escherichia coli is the L7/L12 protein. These phosphoproteins
are collectively called 'P' or 'A' proteins, because they are
highly acidic, which is unusual for ribosomal proteins. P-
proteins exist as dimers in solution, and appear on theDIFFERENTIAL EXPRESSION OF P2 87
ribosome as two dimers - the only polypeptides to be pres-
ent in more than single copies per ribosome (for reviews see
Moller & Maassen, 1986; Liljas et al., 1986). P-proteins have
a distinctive amino acid composition: more than 20%
alanine, only one or two arginines and generally no cysteine
or tryptophan residues. The carboxy-terminal 17 amino acids
of all P-proteins that have been sequenced are very highly
conserved (84%) between yeast and man (Itoh, 1981; Rich &
Steitz, 1987) (see Figure 1). It is this conserved region which
is the antigenic determinant in some patients with the
autoimmune disease systemic lupus erythematosus (Elkon et
al., 1986).
Of all P-proteins the L7/L12 protein from E.coli is the best
studied. It is involved in the interaction of the ribosome with
several translation factors, including the initiation factor IF2,
the elongation factors EF-Tu and EF-G, and the release
factors RFI and RF2 (Weissbach, 1980). The eukaryotic
counterparts P1 and P2 are similar in these respects, and also
in their requirement in whole ribosomes for aminoacyl-tRNA
binding and EF2-dependent GTPase activity, as well as
polypeptide synthesis (MacConnell & Kaplan, 1980, 1982).
There is some evidence that only the phosphorylated forms
of the P-proteins can bind to the ribosome in yeast (Vidales
et al., 1984; Sanchez-Madrid et ai., 1985), and that only
phosphorylated proteins can successfully reconstitute rat liver
ribosomes (MacConnell & Kaplan, 1982; Lavergne et al.,
1987). Vidales et al. (1984) also allude to the effect of pertur-
bations in metabolism being associated with changes in the
proportion of phosphorylated and non-phosphorylated P-
proteins in the ribosome-associated and cytoplasmic pools. If
the P-proteins only function in their phosphorylated state,
then it is possible that disruption of the normal regulatory
pathway for the phosphorylation event could affect the pep-
tide elongation process. If the level of phosphorylation of
these proteins is one regulatory mechanism for the overall
rate of protein elongation, then it is conceivable that changes
in the rate of production of these proteins could upset the
normal control of the protein synthesis. Comparisons can be
drawn with the 40S subunit protein S6, which is phos-
phorylated during periods of tissue regeneration, develop-
ment, cell growth and transformation (Thomas, 1986, and
references therein). This protein is also phosphorylated in
response to various growth factors and purified tyrosine-
specific protein kinases (Thomas et al., 1982; Wettenhall et
al., 1982; Martin-Perez et al., 1984; Maller et al., 1985).
Phosphorylated 40S subunits appear to be utilised more
efficiently in the formation of initiation complexes (Duncan
& McConkey, 1982).
Enhanced expression of ribosomal proteins could be
indicative of a higher rate of overall translation, which may
be related to the proliferation rate of the cells under inves-
tigation. The proliferation rate of the carcinomas used in this
study has been examined previously, and was shown to be
high for six out of the seven carcinomas used (Walker &
Camplejohn, 1986) (Table I). Using DNA flow cytometry,
tumours were classified as being highly proliferative when
more than 14% of cells were in S-phase. Only tumour C3
was classified as medium by this method (Table I). Meyer
(1977) has examined the proliferation rates of fibroadenomas
and carcinomas of the breast by measuring the nuclear incor-
poration of tritiated thymidine. He found that the mitotic
Table I Selected properties ofprimary breast carcinomas used in this
study
Node Menopausal
Tumour Grade" status" status' S-phased
Cl II + pre 14.3
C2 111 n.k. peri/post 14.0
C3 Ill + post 13.1
C4 Ill + peri/post 21.0
C5 Ill + post 20.0
C6 III + n.k. 17.0
C7 11 + pre high
aTumours were graded histologically according to a modification of
the Bloom and Richardson (1957) grading system (Elston et al., 1982).
bNode status: + spread to axillary nodes; n.k., not known.
cMenopausal status defined as pre-, peri- or post-menopausal; n.k. not
known. dS-phase levels are shown as a percentage of tumour cells in
S-phase. Low 0-7%; medium 7- 14%; high over 14%. Data are taken
from Varleyetal. (1987),whereCI isC298; C2 isC300; C3 isC301; C4is
C312; C5 is C317; C6 is C336; and C7 is C378.
activity of fibroadenomas is similar to that of normal breast
tissue, and lower than that of carcinomas. The proliferative
rate of fibroadenomas is negatively correlated with the age of
the patient (Meyer, 1977). In this study, the ages of the
patients from which the fibroadenomas were taken ranged
between 17 and 40 years and no correlation was found
between expression of pLM59-homologous mRNA and age.
The growth rate of fibroadenomas often exceeds carcinomas,
but this can be explained by differences in cell longevity
(Meyer, 1977). It therefore seems unlikely that the increased
level of pLM59 expression seen here in fibroadenomas is due
to the rates of proliferation of the tumour types compared.
The tumour samples used in the construction of the cDNA
libraries and in the screening procedures contained a certain
^amount of infiltrating normal stromal cells and lymphocytes.
These cells would contribute to the patterns of expression
observed, and so may mask the underlying expression pat-
terns in the tumour cells. The stromal lymphocytic infiltrate
has been assayed for the carcinomas used in this study, and
was found to be uniformly low (Whittaker et al., 1986). In
addition, the degree of differentiation, node status and
menopausal status are shown in Table I. Lymphocytic
infiltrate in the fibroadenomas was also very low and so the
relative levels of expression of P2 described here for breast
biopsies are probably not due to the stromal content of the
samples. The tumours were selected primarily on the size,
cellularity and therefore the amount of RNA available from
the biopsy. Within this group of tumours, both grade 3 and
grade 2 tumours were assayed for pLM59 expression, and no
correlation with tumour grade was observed.
The possible mechanism by which altered expression of P2
could be involved with the capability of a cell to metastasise
is unclear at the present. Much more work on the regulation
in normal cells of both expression and function of P-proteins
and the changes that accompany transformation and progres-
sion is needed in order to fully understand whether or not
these proteins play a role in human cancer.
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